COMPARISON OF MONO AND COMBINED EFFECT OF METFORMIN ON OVULATORY RATE IN INFERTILE POLYCYSTIC OVARIAN SYNDROME WOMEN Research Article

Polycystic ovary syndrome affects 7 – 8 % of women and may be the most common cause of infertility. For more than year’s metformin and clomiphene citrate has been the used as a treatment for ovulatory disorders. In recent days aromatase inhibitors have been suggested as an alternative treatment to clomiphene citrate. The aim of this study was to compare the mono and combined effects of metformin and metformin - letrozole on enhanced ovulation and pregnancy rate in infertile patients with polycystic ovary syndrome (PCOS). The patients were visited infertility clinic and examined by gynecologists. Healthy normal cycled women conclude as a control (group I), untreated PCOS patients selected for (group II), All patients in both groups (III and IV) were received 1500 mg metformin per day (500 mg three times a day) for 6–8 weeks. At the end of this period, the patients in the Group IV were received 2.5 mg letrozole for 5 days from day 3 of their menstrual cycle. Primary outcome measures: biochemical and hormonal changes. Secondary outcome measures: Ovulation induction and Pregnancy rate. In this study, the metformin – letrozole group patients LH, FSH and Testosterone levels were significantly reduced after the treatment period. Some biochemical parameters also come stepping back to the normal level. Ovulation occurred in 32 patients (64%) of the metformin – letrozole group and in 16 patients (32%) of the metformin group, which showed a statistically significant difference (P<0.05). A non-significant increase in pregnancy rate was observed in the metformin – letrozole group. Combined therapy of metformin gives beneficial effect on Ovulation rate than the mono therapy of metformin.